Cash Flow Statement (Annual)

HLIX / Helix TCS, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -316 -7,204 -10,595
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation Depletion And Amortization 6 60 479
    Share Based Compensation - - -
    Fair Value Of Convertible Notes - 125 1,201
    Fair Value Adjustment Of Warrants - - 590
    Change In Debt Fair Value - - -
    Gains Losses On Extinguishment Of Debt - - -4,611
    Loss On Beneficial Conversion Feature - - -391
    Goodwill Impairment Loss - 1,278 -
    Gain On Reduction Of Obligation Pursuant To Acquisition - - -
    Increase Decrease In Operating Capital
      Increase Decrease In Accounts Receivable 95 195 411
      Increase Decrease In Prepaid Expense 17 -17 -
      Increase Decrease In Deposits -20 -0 -44
      Increase Decrease In Cost In Excess Of Billing On Uncompleted Contract - - -56
      Increase Decrease In Accounts Payable And Accrued Liabilities -24 -91 311
      Increase Decrease Deferred Rent - 4 5
      Increase Decrease In Billing In Excess Of Cost Of Earnings - - -4
  Net Cash Provided By Used In Operating Activities -476 -1,338 -1,682
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment 34 23 39
  Payments For Previous Acquisition - 172 47
  Net Cash Provided By Used In Investing Activities 478 -195 -1,717
Net Cash Provided By Used In Financing Activities
  Proceeds From Convertible Debt 100 850 229
  Proceeds From Advance From Shareholders - 76 83
  Repayments Of Related Party Debt - - 32
  Proceeds From Notes Payable - - 255
  Proceeds From Issuance Of Debt - - -
  Proceeds From Issuance Of Common Stock - - 100
  Net Cash Provided By Used In Financing Activities 152 1,437 4,209
Cash And Cash Equivalents Period Increase Decrease - -96 811
Cash And Cash Equivalents At Carrying Value - 58 869

Peers -

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...